Logo image of VCYT

VERACYTE INC (VCYT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VCYT - US92337F1075 - Common Stock

44.61 USD
-2.8 (-5.91%)
Last: 12/5/2025, 8:00:01 PM
44.23 USD
-0.38 (-0.85%)
Pre-Market: 12/8/2025, 7:00:00 AM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to VCYT. VCYT was compared to 531 industry peers in the Biotechnology industry. While VCYT has a great health rating, its profitability is only average at the moment. VCYT is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes VCYT very considerable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

VCYT had positive earnings in the past year.
In the past year VCYT had a positive cash flow from operations.
VCYT had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: VCYT reported negative operating cash flow in multiple years.
VCYT Yearly Net Income VS EBIT VS OCF VS FCFVCYT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

VCYT has a Return On Assets of 2.22%. This is amongst the best in the industry. VCYT outperforms 89.08% of its industry peers.
The Return On Equity of VCYT (2.41%) is better than 90.21% of its industry peers.
VCYT's Return On Invested Capital of 2.93% is amongst the best of the industry. VCYT outperforms 89.83% of its industry peers.
Industry RankSector Rank
ROA 2.22%
ROE 2.41%
ROIC 2.93%
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
VCYT Yearly ROA, ROE, ROICVCYT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

VCYT has a Profit Margin of 6.12%. This is amongst the best in the industry. VCYT outperforms 90.02% of its industry peers.
VCYT's Operating Margin of 9.70% is amongst the best of the industry. VCYT outperforms 91.53% of its industry peers.
With an excellent Gross Margin value of 68.53%, VCYT belongs to the best of the industry, outperforming 80.98% of the companies in the same industry.
In the last couple of years the Gross Margin of VCYT has remained more or less at the same level.
Industry RankSector Rank
OM 9.7%
PM (TTM) 6.12%
GM 68.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
VCYT Yearly Profit, Operating, Gross MarginsVCYT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), VCYT is destroying value.
VCYT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VCYT has more shares outstanding
There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VCYT Yearly Shares OutstandingVCYT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
VCYT Yearly Total Debt VS Total AssetsVCYT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 19.59 indicates that VCYT is not in any danger for bankruptcy at the moment.
VCYT has a better Altman-Z score (19.59) than 88.32% of its industry peers.
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 19.59
ROIC/WACC0.33
WACC8.78%
VCYT Yearly LT Debt VS Equity VS FCFVCYT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 6.23 indicates that VCYT has no problem at all paying its short term obligations.
The Current ratio of VCYT (6.23) is better than 64.22% of its industry peers.
A Quick Ratio of 5.94 indicates that VCYT has no problem at all paying its short term obligations.
VCYT's Quick ratio of 5.94 is fine compared to the rest of the industry. VCYT outperforms 63.09% of its industry peers.
Industry RankSector Rank
Current Ratio 6.23
Quick Ratio 5.94
VCYT Yearly Current Assets VS Current LiabilitesVCYT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 353.33% over the past year.
VCYT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.41%.
Measured over the past years, VCYT shows a very strong growth in Revenue. The Revenue has been growing by 29.93% on average per year.
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%

3.2 Future

Based on estimates for the next years, VCYT will show a very strong growth in Earnings Per Share. The EPS will grow by 52.24% on average per year.
Based on estimates for the next years, VCYT will show a quite strong growth in Revenue. The Revenue will grow by 11.54% on average per year.
EPS Next Y74.53%
EPS Next 2Y86.75%
EPS Next 3Y59.6%
EPS Next 5Y52.24%
Revenue Next Year14.36%
Revenue Next 2Y12.54%
Revenue Next 3Y12.19%
Revenue Next 5Y11.54%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VCYT Yearly Revenue VS EstimatesVCYT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
VCYT Yearly EPS VS EstimatesVCYT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 117.39, the valuation of VCYT can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 89.45% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.49. VCYT is valued rather expensively when compared to this.
VCYT is valuated quite expensively with a Price/Forward Earnings ratio of 42.64.
91.15% of the companies in the same industry are more expensive than VCYT, based on the Price/Forward Earnings ratio.
VCYT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.69.
Industry RankSector Rank
PE 117.39
Fwd PE 42.64
VCYT Price Earnings VS Forward Price EarningsVCYT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, VCYT is valued cheaply inside the industry as 91.15% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 93.22% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 35.91
EV/EBITDA 44.17
VCYT Per share dataVCYT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
VCYT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VCYT's earnings are expected to grow with 59.60% in the coming years.
PEG (NY)1.58
PEG (5Y)N/A
EPS Next 2Y86.75%
EPS Next 3Y59.6%

0

5. Dividend

5.1 Amount

No dividends for VCYT!.
Industry RankSector Rank
Dividend Yield N/A

VERACYTE INC

NASDAQ:VCYT (12/5/2025, 8:00:01 PM)

Premarket: 44.23 -0.38 (-0.85%)

44.61

-2.8 (-5.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-23 2026-02-23/amc
Inst Owners114.7%
Inst Owner Change3.31%
Ins Owners0.46%
Ins Owner Change-2.17%
Market Cap3.53B
Revenue(TTM)495.14M
Net Income(TTM)30.32M
Analysts82.11
Price Target49.33 (10.58%)
Short Float %6.93%
Short Ratio5.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-110.32%
Max EPS beat(2)79.03%
EPS beat(4)2
Avg EPS beat(4)-1.91%
Min EPS beat(4)-110.32%
Max EPS beat(4)79.03%
EPS beat(8)5
Avg EPS beat(8)108.97%
EPS beat(12)8
Avg EPS beat(12)67.3%
EPS beat(16)12
Avg EPS beat(16)58.01%
Revenue beat(2)2
Avg Revenue beat(2)4.54%
Min Revenue beat(2)3.31%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)11
Avg Revenue beat(12)4.6%
Revenue beat(16)15
Avg Revenue beat(16)5.32%
PT rev (1m)14.88%
PT rev (3m)17.32%
EPS NQ rev (1m)8.52%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)31.06%
EPS NY rev (3m)39.68%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)1.31%
Revenue NY rev (3m)1.6%
Valuation
Industry RankSector Rank
PE 117.39
Fwd PE 42.64
P/S 7.12
P/FCF 35.91
P/OCF 32.58
P/B 2.8
P/tB 8.86
EV/EBITDA 44.17
EPS(TTM)0.38
EY0.85%
EPS(NY)1.05
Fwd EY2.35%
FCF(TTM)1.24
FCFY2.78%
OCF(TTM)1.37
OCFY3.07%
SpS6.26
BVpS15.91
TBVpS5.04
PEG (NY)1.58
PEG (5Y)N/A
Graham Number11.66
Profitability
Industry RankSector Rank
ROA 2.22%
ROE 2.41%
ROCE 3.71%
ROIC 2.93%
ROICexc 4.08%
ROICexgc 54.52%
OM 9.7%
PM (TTM) 6.12%
GM 68.53%
FCFM 19.83%
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score8
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 44.87%
Cap/Sales 2.03%
Interest Coverage 250
Cash Conversion 153.79%
Profit Quality 323.94%
Current Ratio 6.23
Quick Ratio 5.94
Altman-Z 19.59
F-Score8
WACC8.78%
ROIC/WACC0.33
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y74.53%
EPS Next 2Y86.75%
EPS Next 3Y59.6%
EPS Next 5Y52.24%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
Revenue Next Year14.36%
Revenue Next 2Y12.54%
Revenue Next 3Y12.19%
Revenue Next 5Y11.54%
EBIT growth 1Y426.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year319.96%
EBIT Next 3Y74.15%
EBIT Next 5Y47.08%
FCF growth 1Y237.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.75%
OCF growth 3YN/A
OCF growth 5YN/A

VERACYTE INC / VCYT FAQ

What is the fundamental rating for VCYT stock?

ChartMill assigns a fundamental rating of 6 / 10 to VCYT.


What is the valuation status for VCYT stock?

ChartMill assigns a valuation rating of 6 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.


How profitable is VERACYTE INC (VCYT) stock?

VERACYTE INC (VCYT) has a profitability rating of 6 / 10.


How financially healthy is VERACYTE INC?

The financial health rating of VERACYTE INC (VCYT) is 8 / 10.


What is the expected EPS growth for VERACYTE INC (VCYT) stock?

The Earnings per Share (EPS) of VERACYTE INC (VCYT) is expected to grow by 74.53% in the next year.